US Begins Clinical Trial Evaluating Antiviral for Monkeypox

September 9, 2022 by Dan McCue
US Begins Clinical Trial Evaluating Antiviral for Monkeypox
Colorized scanning electron micrograph of monkeypox virus (green) on the surface of infected VERO E6 cells (blue). Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID

WASHINGTON — A phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infections in the United States, the National Institutes of Health announced Friday.

Study investigators aim to enroll more than 500 people from clinical research sites nationwide. Interested volunteers can visit the ACTG website (clinical trial A5418) for more information.

Tecovirimat, manufactured by SIGA Technologies, Inc., is approved by the U.S. Food and Drug Administration for the treatment of smallpox. 

The drug prevents the virus from spreading in the body by preventing virus particles from exiting human cells by targeting a protein found on both the variola virus, which causes smallpox, and the monkeypox virus. 

Clinicians currently can access tecovirimat for U.S. patients with monkeypox through an expanded access or “compassionate use” request process.

“Monkeypox can be an extremely painful infection that lasts for weeks,” said NIAID Director Dr. Anthony Fauci, in a written statement. 

“We currently lack efficacy data that would help us understand how well this drug may mitigate painful monkeypox symptoms and prevent serious outcomes. This clinical trial was designed to answer those important questions,” Fauci said.

A global outbreak of human monkeypox virus, first identified in May 2022, prompted public health emergency declarations from both the World Health Organization and the U.S. Department of Health and Human Services this past summer.

The majority of cases identified thus far have been in men who have sex with men, although other populations, including women and children, can become infected. 

Since Jan. 1, the WHO has reported 52,996 cases and 18 deaths across 102 countries, territories and areas. The Centers for Disease Control and Prevention has reported 21,504 cases in the U.S.

The clinical trial of tecovirimat in the United States is led by Dr. Timothy Wilkin, professor of medicine at Weill Cornell Medicine in New York City. 

Adults and children of any age with monkeypox are eligible to enroll in the trial. Adults with severe monkeypox virus infection or those at high risk for severe disease including individuals with underlying immune deficiency, a history of or active inflammatory skin conditions, pregnant people and children all will be enrolled in an open-label arm in which all participants receive tecovirimat.

Other adult participants — 530 total — will be randomly assigned in a 2:1 ratio to receive tecovirimat or placebo pills. Tecovirimat capsules are taken by mouth for 14 days, and the dose is based on the participant’s weight. This part of the trial is double-blind, meaning neither participants nor investigators will know who is receiving the placebo or tecovirimat.

Investigators will gather data to determine if participants receiving tecovirimat heal more quickly (all lesions scabbed over or flaked off) compared with those taking the placebo. They also will examine tecovirimat’s impact on pain scores, rates of progression to severe disease, clearance of monkeypox virus from various samples, and its safety, among other data. This study also will provide critical data on the optimal dosing and safety of tecovirimat in children and people who are pregnant. 

Participants will be followed for at least eight weeks and will be asked to fill out a symptom diary, do daily skin checks at home and attend virtual and in-person clinic appointments. They also will undergo physical exams and will be asked to provide blood and other bodily fluid samples, including swabbing fluid from their lesions. 

Data on the safety and efficacy of tecovirimat will be submitted to the FDA. An independent Data and Safety Monitoring Board will monitor participant safety throughout the duration of the study.

The trial timeline will depend on the pace of enrollment. This research is supported through the following NIAID grants: UM1AI068636, UM1AI106701 and UM1AI068634, and NICHD contract number HHSN275201800001I. 

The Democratic Republic of the Congo will initiate a separate clinical trial of tecovirimat in adults and children with monkeypox in that country. More information about that trial will be available in a forthcoming announcement. 

The trial is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. 

The NIAID-funded AIDS Clinical Trials Group is leading the study, which may later expand to international sites. 

The Eunice Kennedy Shriver National Institute of Child Health and Human Development at NIH is supporting several sites, including through the International Maternal Pediatric Adolescent AIDS Clinical Trials Network.

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue.

A+
a-
  • clinical trial
  • monkeypox
  • National Institutes of Health
  • In The News

    Health

    Voting

    Health

    New Trump Vaccine Policy Limits Access to COVID Shots

    WASHINGTON (AP) — The Trump administration said Tuesday it will limit approval for seasonal COVID-19 shots to seniors and others at high risk pending... Read More

    WASHINGTON (AP) — The Trump administration said Tuesday it will limit approval for seasonal COVID-19 shots to seniors and others at high risk pending more data on everyone else — raising questions about whether some people who want a vaccine this fall will be able to get one. Top officials... Read More

    Choose Wisely: Medicaid Cuts Could Cripple Trump’s America First Agenda

    In Washington, D.C., there is one rule you can count on: nothing is ever as it seems. The mirage of... Read More

    In Washington, D.C., there is one rule you can count on: nothing is ever as it seems. The mirage of smoke and mirrors provides the ambiance, but not the needed reflection. The current debate over cutting Medicaid is no different. It’s not just a budget fight... Read More

    After US Cuts Funding, WHO Chief Defends $2.1B Budget Request by Comparing It With Cost of War

    GENEVA (AP) — Stripped of U.S. funding, the World Health Organization chief on Monday appealed to member countries to support its “extremely... Read More

    GENEVA (AP) — Stripped of U.S. funding, the World Health Organization chief on Monday appealed to member countries to support its “extremely modest” request for a $2.1 billion annual budget by putting that sum into perspective next to outlays for ad campaigns for tobacco or the cost of... Read More

    May 19, 2025
    by Jesse Zucker
    Fitness and Nutrition Guide to GLP-1s

    WASHINGTON — Many people face challenges when trying to maintain a healthy weight. Over the last few years, GLP-1 medications,... Read More

    WASHINGTON — Many people face challenges when trying to maintain a healthy weight. Over the last few years, GLP-1 medications, originally intended for type 2 diabetes, have shown promising results in helping with weight loss. However, weight alone isn’t the whole story when it comes to... Read More

    May 19, 2025
    by Jesse Zucker
    When It Comes to Sleep, Quality Matters

    WASHINGTON — Do you ever feel like your brain slows down the day after a bad night’s sleep? It’s not... Read More

    WASHINGTON — Do you ever feel like your brain slows down the day after a bad night’s sleep? It’s not just your imagination. A new review suggests how sleep quality early in life may influence brain development and cognitive performance in school. Here, we will take... Read More

    Reform Supplemental Oxygen for Chronically Ill Patients

    For the 1.5 million Americans living with chronic lung and heart disease and other respiratory conditions, supplemental oxygen is not... Read More

    For the 1.5 million Americans living with chronic lung and heart disease and other respiratory conditions, supplemental oxygen is not a luxury or something that would be nice to have — it is a literal lifeline. Supplemental oxygen allows patients to live more active, independent lives... Read More

    News From The Well
    scroll top